Immunocore/$IMCR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Immunocore

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Ticker

$IMCR
Sector
Health
Primary listing
NASDAQ

Employees

493
Headquarters
Abingdon, United Kingdom
Website
www.immunocore.com

Immunocore Metrics

BasicAdvanced
$1.7B
-
-$0.41
-
-

What the Analysts think about Immunocore

Analyst ratings (Buy, Hold, Sell) for Immunocore stock.

Bulls say / Bears say

KIMMTRAK net product sales reached $98.0 million in Q2 2025, a 30% year-over-year increase driven by a 15% uplift in the U.S. and strong demand in Europe (Nasdaq)
Cash, cash equivalents and marketable securities totaled $882.8 million as of June 30, 2025, up from $820.4 million at year-end 2024, ensuring substantial runway for ongoing clinical trials (Nasdaq)
The Phase 3 TEBE-AM trial is on track to complete enrollment in the first half of 2026; dose selection for the PRISM-MEL-301 trial is expected in the second half of 2025, and Phase 1 HBV data for IMC-I109V will be presented at AASLD 2025, demonstrating solid clinical progress (Nasdaq)
Net loss of $10.3 million in Q2 2025, alongside R&D expenses of $69.0 million and SG&A of $42.8 million, highlights continued pressure on profitability and margins (Nasdaq)
Topline data from pivotal Phase 3 trials (TEBE-AM and PRISM-MEL-301) are not expected until 2026, delaying the prospect of additional revenue streams beyond KIMMTRAK (Nasdaq)
Expected payment of approximately $65 million in sales-related rebate accruals in the second half of 2025 may significantly erode cash reserves and limit financial flexibility (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

Immunocore Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immunocore Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Immunocore News

AllArticlesVideos
Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Growth Picks: 3 Low-Cost Stocks That Could Double in Value

MarketBeat3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMCR

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs